Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes Mellitus When Failing on OADs

A Titrate-To-Target Study of the Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Mellitus Not Achieving Glycaemic Targets on OADs With / Without Once Daily Basal Insulin Therapy

This trial is conducted in Europe.

This is a clinical trial investigating the effectiveness and the safety of using biphasic insulin aspart 30 both for initiation and intensification of insulin treatment in type 2 diabetes.

Inclusion Criteria:

• Type 2 Diabetes Mellitus for more than 12 months
• HbA1c: 7.5 - 11.0%
• An antidiabetic regimen that has been stable for at least 3 months prior to screening
• An antidiabetic regimen that includes a minimum of 2 oral anti-diabetic drugs (OADs) or 1 OAD plus evening or bedtime basal insulin
• OADs dosed at 50% or more of the maximum recommended dose

Exclusion Criteria:

• Use of any insulin preparations other than NPH or glargine within the past 6 months
• Use of more than 60 units of insulin per day
• Morning time insulin administration
• Use of more than one insulin dose daily